CME

Faculty: Susana Campos, MD, MPH

Faculty: Robert Coleman, MD, FACOG

Faculty: Debra Richardson, MD

This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants will apply biomarker insights to guide treatment strategies in both frontline maintenance and platinum-resistant settings. Faculty emphasize patient selection, sequencing strategies, and interpretation of clinical data within real-world practice constraints. The program also highlights proactive approaches to identifying and managing treatment-related adverse events to support adherence and quality of life. This activity equips clinicians with practical tools to integrate biomarker findings, clinical evidence, and patient-centered considerations into individualized ovarian cancer care.

Faculty: Andrea Lora Kossler, MD, FACS

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Andrea Lora Kossler, MD, FACS

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment intensification, including androgen deprivation therapy–based combination approaches and the earlier use of androgen receptor pathway inhibitors in patients with high-risk disease. They also explore how advances in imaging, multidisciplinary care, and emerging clinical evidence are shaping treatment selection and timing. In addition, the discussion addresses practical considerations for managing adverse events associated with intensified therapy and incorporating these strategies into clinical practice.